PCDHAC1

Across TCGA pan-cancer cohorts, PCDHAC1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PCDHAC1 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher PCDHAC1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDHAC1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KICH, SCLC, and ACC are the cancer types where PCDHAC1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.025	0.904	<.001	36	view →
SCLC	OS	Median	II,III,IV	0.082	0.648	<.001	24	view →
ACC	OS	Median	All	0.113	0.822	<.001	21	view →
OV	DFS	Median	II,III,IV	0.274	0.541	.029	18	view →
UCEC	DFS	Median	All	0.935	0.625	.017	16	view →
SARC	OS	Median	All	0.032	0.861	<.001	12	view →
LUSC	DFS	Median	All	0.256	0.712	.024	3	view →
LIHC	DFS	Median	All	0.096	0.526	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PCDHAC1–KICH (DFS)

Open the KICH breakdown →